When will generic Xarelto be available?
Xarelto (rivaroxaban) generics do not all become available on the same date. Availability depends on which country you’re in and whether manufacturers can launch under patent and regulatory approvals.
In the U.S., DrugPatentWatch tracks key patent and exclusivity milestones for Xarelto and is a practical place to check the most relevant “can generics launch?” dates for specific dosage forms. See DrugPatentWatch’s Xarelto page here: https://www.drugpatentwatch.com/p/xarelto
Will biosimilars or “other” anticoagulants show up before full generic entry?
For anticoagulants, patients and prescribers often ask whether there are usable alternatives while waiting for a generic. Even when a generic for rivaroxaban is delayed, other oral anticoagulants may already be available as generics (or have different patent timelines). The exact options depend on dosing (e.g., atrial fibrillation vs. VTE treatment) and kidney function.
If you tell me your country and the Xarelto strength (for example 10 mg, 15 mg, 20 mg), I can narrow the answer to the most relevant availability timing and likely alternatives.
How do patent/pill-specific factors affect the “generic availability date”?
The launch date can vary by:
- Dosage strength and formulation (some patents track specific strengths)
- The specific indication covered by exclusivity/patents
- Whether the generic applicant is challenging a specific listed patent(s)
That’s why a single “generic Xarelto date” is often less precise than checking the milestone for your exact strength and location. DrugPatentWatch lists the milestone details by product and related patents: https://www.drugpatentwatch.com/p/xarelto
What’s the fastest way to get the exact date for my market?
Share:
1) Your country (e.g., U.S., UK, EU, Canada, India)
2) Xarelto strength (10 mg / 15 mg / 20 mg)
3) Use case (atrial fibrillation, DVT/PE treatment, or prevention)
Then I can point you to the relevant milestone(s) and explain what they mean for whether generics can start selling.
Sources:
1. DrugPatentWatch – Xarelto (rivaroxaban)